Bank of New York Mellon Corp Acquires 15,006 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Bank of New York Mellon Corp lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 671,630 shares of the biopharmaceutical company’s stock after purchasing an additional 15,006 shares during the quarter. Bank of New York Mellon Corp owned 0.63% of Regeneron Pharmaceuticals worth $377,638,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. CoreCap Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 9.2% during the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock valued at $134,000 after acquiring an additional 20 shares during the period. Strait & Sound Wealth Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 3.5% during the third quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock valued at $353,000 after purchasing an additional 21 shares during the last quarter. Parkside Financial Bank & Trust lifted its position in Regeneron Pharmaceuticals by 14.8% during the third quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 21 shares during the period. Independence Bank of Kentucky boosted its holdings in Regeneron Pharmaceuticals by 7.7% in the third quarter. Independence Bank of Kentucky now owns 308 shares of the biopharmaceutical company’s stock worth $173,000 after purchasing an additional 22 shares during the last quarter. Finally, Redwood Wealth Management Group LLC grew its position in Regeneron Pharmaceuticals by 4.8% in the 2nd quarter. Redwood Wealth Management Group LLC now owns 506 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 23 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on REGN shares. Truist Financial raised their price target on Regeneron Pharmaceuticals from $798.00 to $820.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Citigroup raised their target price on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Wells Fargo & Company upped their price target on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an “equal weight” rating in a research report on Wednesday, December 10th. Royal Bank Of Canada raised their price objective on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. Finally, UBS Group upped their target price on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $784.77.

Regeneron Pharmaceuticals Stock Down 0.2%

Shares of REGN stock opened at $749.44 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $821.11. The company’s fifty day moving average price is $758.68 and its 200-day moving average price is $648.66. The company has a market capitalization of $78.77 billion, a price-to-earnings ratio of 17.95, a PEG ratio of 1.96 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same quarter in the prior year, the business posted $12.46 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up .9% compared to the same quarter last year. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.